The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Mechanisms mediating the negative interaction between oxaliplatin (Ox) and epidermal growth factor receptor (EGFR) inhibitors in patients (pts) with KRAS mutant (MT) colorectal cancer (CRC).
Daniel J. Freeman
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Selam Ogbagabriel
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jiansong Xie
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Gloria Juan
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Nicholas Potter
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Josh Dekeyser
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Robert Radinsky
Employment or Leadership Position - Amgen
Stock Ownership - Amgen